Treatment of Waldenstrom's Macroglobulinemia with Rituximab: Prognostic Factors for Response and Progression

References

• Dimopoulos, M.A., Panayiotidis, P., Moulopoulos, L.A., Sfikalcis, P. and Dalakas, M. (2000) "Waldenstrom's macroglobulinemia: clinical features, complications, and management", Journal of Clinical Oncology, 18, 214–226.
   PubMed Web of Science ®Google Scholar
• Kyle, R.A., Greipp, P.R., Gertz, M.A., Witzig, T.E., Lust, JA., Lacy, M.O., et al. (2000) "Waldenstrom's macroglobulinemia: a prospective study comparing daily with intermittent oral Chlor-ambucil", British Journal of Haematology, 108, 737–742.
   Google Scholar
• Dimopoulos, MA., Kantarjian, H., Weber, D., O'Brien, S., Estey, E., Delasalle, K., et al. (1994) "Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine", Journal of Clin-ical Oncology, 12, 2694–2698.
   Google Scholar
• Dhodapkar, M.V., Jacobson, J.L., Gertz, M.A., Rivkin, SE., Roodman, G.D., Tuscano, J.M., et al. (2001) "Prognostic factors and response to fludarabine therapy in patients with Waldenstrom's macroglobulinemia: results of United States Intergroup trial (South West Oncology Group S 9003)", Blood, 98, 41–48.
   Google Scholar
• Jensen, G.S., Andrews, E.J., Mant, M.J. and Pilarslci, L. (1991) "Transitions in CD 45 isoform expression indicate continuous differentiation of a monoclonal CD5 + CD11b + B lineage in Waldenstrom's macroglobulinemia", American Journal of Hematol-ogy, 37, 20–30.
   PubMed Web of Science ®Google Scholar
• Maloney, D.G., Grillo-Lopez, A.J., White, CA., Bodkin, D., Schilder, R.J., Neidhart, J.A., et al. (1997) "IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma", Blood, 90, 2188–2195.
   PubMed Web of Science ®Google Scholar
• McLaughlin, P., Grillo-Lopez, A.J., Link, BK., Levy, R., Czucz-man, M.S., Williams, M.E., et al. (1998) "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lympho-ma: half of the patients respond to a four-dose treatment program", Journal of Clinical Oncology, 16, 2825–2833.
   PubMed Web of Science ®Google Scholar
• Byrd, J.C., White, C.A., Link, B., Lucas, M.S., Velasquez, W.S., Rosenberg, J., et al. (1999) "Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity", Annals of Oncology, 10, 1525 — 1527.
   Google Scholar
• Weber, D.M., Gavino, M., Huh, Y. and Alexanian, R. (1999) "Phenotypic and clinical evidence supports rituximab for Walden-strom's macroglobulinemia", Blood, 94, 125a(abstr).
   Google Scholar
• Treon, S.P., Agus, TB., Link, B., Rodrigues, G., Molina, A., Lacy, M.O., et al. (2001) "CD20-directed antibody-mediated immunother-apy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia", Journal of Immunotherapy, 24, 272–279.
   Web of Science ®Google Scholar
• Dimopoulos, M.A., Zervas, C., Zomas, A., Kiamouris, C., Viniou, N.A., Grigoralci, V., et al. (2002) "Treatment of Waldenstrom's macroglobulinemia with rituximab", Journal of Clinical Oncology, 20, 2327 — 2333.
   PubMed Web of Science ®Google Scholar
• Treon, S., Emmanouilides, C., Kimby, E., Kelliher, A., Preffer, F., Freeman, A., et al. (2002) "Extended rituximab therapy is highly active and facilitates hematologic recovery in patients with lymphoplasmacytic lymphoma (Waldenstrom's macroglobuline-mia)", Proceedings of the American Society of Clinical Oncology, 21, 268a(abstract).
   Google Scholar
• Dimopoulos, MA., Zervas, C., Zomas, A., Hamilos, G., Gika, D., Efsthathiou, E., et al. (2002) "Extended rituximab therapy for previously untreated patient's with Waldenstrom's macroglobuline-mia", Clinical Lymphoma, 3, 163–166.
   Google Scholar
• Harris, N.L., Jaffe, ES., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J. (1999) "World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting—Airlie House, Virginia, November 1997", Journal of Clinical Oncology, 17, 3835–3849.
   PubMed Web of Science ®Google Scholar
• Owen, R.G., Treon, S., Al-Katib, A., Fonseca, R., Greipp, P.R., McMaster, ML., et al. (2003) "Clinico-pathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommenda-tions from the Second International Workshop on Waldenstrom's Macroglobulinemia", Seminars in Oncology, 30, 110 — 115.
   Google Scholar
• Weber, D., Treon, S., Emmanouilides, C., Branagan, A.R., Byrd, J.C., Blade, J., et al. (2003) "Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus Panel recommenda-tions from the Second International Workshop Waldenstrom's macroglobulinemia", Seminars in Oncology, 30, 121–126.
   Google Scholar
• Kaplan, E.S. and Meier, P. (1958) "Non-parametric estimation for incomplete observation", Journal of the American Statistical Association, 53, 143–151.
   Google Scholar
• Cox, R. (1972) "Regression models and life tables", Journal of Royal Statistical Society Bulletin, 34, 187–220.
   Web of Science ®Google Scholar
• Boye, J., Elter, T. and Engert, A. (2003) "An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab", Annals of Oncology, 14, 520— 535.
   Google Scholar
• Weber, D.M., Dimopoulos, M.A., Delasalle, K., Rankin, K., Gavino, M., Alexanian, R. (2003) "2-Chloradeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia", Seminars in Oncology, 30, 243–247.
   PubMed Web of Science ®Google Scholar
• Treon, S.P., Wasi, P., Emmanouilides, CA., Frankel, SR., Kimby, E., Lister, A., et al. (2002) "Combination therapy with rituximab and fludarabine is highly active in Waldentrom's macroglobuline-mia", Blood, 100, 211a(abstr 794).
   Google Scholar
• O'Brien, S.M., Kantarjian, H., Thomas, D.A., Giles, F.J., Freireich, E.J., Cortes, J., et al. (2001) "Rituximab dose-escalation trial in chronic lymphocytic leukemia", Journal of Clinical Oncology, 19, 2165–2170.
   PubMed Web of Science ®Google Scholar